Literature DB >> 1483461

Metabolic effects of short-chain ceramide and glucosylceramide on sphingolipids and protein kinase C.

A Abe1, D Wu, J A Shayman, N S Radin.   

Abstract

Recent studies have identified a potential role for glucosylceramide (GlcCer) in growth promotion and hormonal signalling. In an effort to demonstrate a growth-promoting activity of GlcCer, we prepared a GlcCer having a short-chain acid (octanoyl), in the belief that this glycolipid could be absorbed more readily and more uniformly by cultured cells. By using a mixture of two specific lecithins, dioleoylglycerophosphocholine and 1-stearoyl-2-palmitoylglycerophosphocholine, we were able to prepare dispersions containing a high molar proportion of the GlcCer and the related ceramide, octanoyl sphingosine. Unexpectedly, both sphingolipids inhibited protein and DNA synthesis in Madin-Darby canine kidney cells and produced large increases in the levels of the natural lipids, GlcCer, ceramide, free sphingosine, and an amine that may be glucosylsphingosine (GlcSph). Decreases were seen in the level of sphingomyelin and the proportion of protein kinase C in the cell membranes. The level of lactosylceramide was diminished by octanoyl GlcCer but elevated considerably by octanoyl sphingosine. Diacylglycerols were increased by the lecithins in the liposomes, but the exogenous sphingolipids had no effect. Octanoyl sphingosine labeled in the sphingoid base yielded labeled GlcCer and sphingomyelin labeled in both long-chain and very-long-chain fatty acid families, as well as the octanoyl version. The two families of ceramides, however, had relatively little radioactivity. Some of these changes are attributed to rapid hydrolysis of the added lipids with the formation, particularly from the ceramide, of sphingosine and its anabolic metabolite, GlcSph. Several observations support the idea that the octanoyl sphingosine inhibited the phosphocholinetransferase that synthesizes sphingomyelin while the octanoyl GlcCer inhibited GlcCer beta-glucosidase and GlcCer galactosyltransferase. The use of unnatural short-chain lipids in the study of cell growth and other phenomena may result in unexpected changes in related metabolites and the findings from such experiments should therefore be interpreted cautiously.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1483461     DOI: 10.1111/j.1432-1033.1992.tb17479.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  13 in total

1.  Lipid metabolic changes caused by short-chain ceramides and the connection with apoptosis.

Authors:  D Allan
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

2.  Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approaches.

Authors:  Jacqueline V Chapman; Valérie Gouazé-Andersson; Maria C Messner; Margaret Flowers; Ramin Karimi; Mark Kester; Brian M Barth; Xin Liu; Yong-Yu Liu; Armando E Giuliano; Myles C Cabot
Journal:  Biochem Pharmacol       Date:  2010-04-10       Impact factor: 5.858

Review 3.  Glucosylceramide in the nervous system--a mini-review.

Authors:  N S Radin
Journal:  Neurochem Res       Date:  1994-05       Impact factor: 3.996

Review 4.  Protein kinase C targeting in antineoplastic treatment strategies.

Authors:  W D Jarvis; S Grant
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

5.  Anti-proliferative effects of tricyclodecan-9-yl-xanthogenate (D609) involve ceramide and cell cycle inhibition.

Authors:  Anchal Gusain; James F Hatcher; Rao Muralikrishna Adibhatla; Umadevi V Wesley; Robert J Dempsey
Journal:  Mol Neurobiol       Date:  2012-03-14       Impact factor: 5.590

6.  Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.

Authors:  Samy A F Morad; Su-Fern Tan; David J Feith; Mark Kester; David F Claxton; Thomas P Loughran; Brian M Barth; Todd E Fox; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2015-03-10

7.  Long-chain ceramide produced in response to N-hexanoylsphingosine does not induce apoptosis in CHP-100 cells.

Authors:  Adriano Mancinetti; Sabrina Di Bartolomeo; Angelo Spinedi
Journal:  Lipids       Date:  2009-09-26       Impact factor: 1.880

8.  Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53.

Authors:  Samy A F Morad; James P Madigan; Jonathan C Levin; Noha Abdelmageed; Ramin Karimi; Daniel W Rosenberg; Mark Kester; Sriram S Shanmugavelandy; Myles C Cabot
Journal:  Biochem Pharmacol       Date:  2013-01-24       Impact factor: 5.858

9.  Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells.

Authors:  Valérie Gouazé-Andersson; Jing Y Yu; Adam J Kreitenberg; Alicja Bielawska; Armando E Giuliano; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2007-11-09

Review 10.  Killing tumours by ceramide-induced apoptosis: a critique of available drugs.

Authors:  Norman S Radin
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.